EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Levosimendan, a Promising Pharmacotherapy in Cardiogenic Shock: A Comprehensive Review

Hendri Susilo, Fan Maitri Aldian, Citrawati Dyah Kencono Wungu, Mochamad Yusuf Alsagaff, Henry Sutanto, Chaq El Chaq Zamzam Multazam

European Cardiology Review · 12.11.2024 · 19

DOI: 10.15420/ecr.2024.16 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Cardiology Review, online erschienen am 12.11.2024. Verfasst von Hendri Susilo und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Airlangga Surabaya, Indonesia. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cardiogenic shock (CS) is a critical condition with high mortality rate, as the current management of CS presents significant challenges. Exploration of more effective therapies is necessitated. This review article comprehensively examines the efficacy and safety of levosimendan in the management of CS. By synthesising evidence from numerous studies, a comparison of levosimendan over traditional inotropic agents, such as enoximone, dobutamine, dopamine and norepinephrine, is highlighted. The unique mechanism of action of levosimendan enhances myocardial contractility without increasing oxygen demand, offering a promising alternative for patients with CS. This review also delves into comparative studies that demonstrate the superiority of levosimendan in improving survival rates, haemodynamic parameters, and reducing the incidence of CS complications. Safety profiles and adverse effects are critically assessed to provide a balanced view of the therapeutic window provided by levosimendan. The review concludes that levosimendan is a valuable addition to the therapeutic strategy against CS, with the potential to improve patient outcomes.

Schlagwörter

Stichwörter der Autor:innen

Levosimendanadenosine triphosphate-dependent potassium channel openercalcium sensitisercardiogenic shockcardiovascular disease

Autor:innen und Institutionen

  • Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Airlangga Surabaya, Indonesia.
  • Department of Cardiology and Vascular Medicine, Universitas Airlangga Hospital Surabaya, Indonesia.
  • Faculty of Medicine, Universitas Airlangga Surabaya, Indonesia.
  • Department of Physiology and Medical Biochemistry, Faculty of Medicine, Universitas Airlangga Surabaya, Indonesia.
  • Institute of Tropical Disease, Universitas Airlangga Surabaya, Indonesia.
  • Department of Internal Medicine, Faculty of Medicine, Universitas Airlangga Surabaya, Indonesia.

Zitieren

APA

Susilo, H., Aldian, F. M., Wungu, C. D. K., Alsagaff, M. Y., Sutanto, H., & Multazam, C. E. C. Z. (2024). Levosimendan, a Promising Pharmacotherapy in Cardiogenic Shock: A Comprehensive Review. European Cardiology Review, 19. https://doi.org/10.15420/ecr.2024.16

Vancouver

Susilo H, Aldian FM, Wungu CDK, Alsagaff MY, Sutanto H, Multazam CECZ. Levosimendan, a Promising Pharmacotherapy in Cardiogenic Shock: A Comprehensive Review. European Cardiology Review. 2024;19. doi:10.15420/ecr.2024.16

BibTeX
@article{Susilo2024,
  author = {Susilo, Hendri and Aldian, Fan Maitri and Wungu, Citrawati Dyah Kencono and Alsagaff, Mochamad Yusuf and Sutanto, Henry and Multazam, Chaq El Chaq Zamzam},
  title = {Levosimendan, a Promising Pharmacotherapy in Cardiogenic Shock: A Comprehensive Review},
  journal = {European Cardiology Review},
  year = {2024},
  volume = {19},
  doi = {10.15420/ecr.2024.16}
}
Kostenlos starten →